Dirk Kreder is a Ph.D. from the life sciences by training and holds an International Executive MBA.
He worked more than 15 years for biotech and global pharma companies in the US, Switzerland, and Germany. Dirk is a seasoned expert in biotechnology industry. Prior to founding anteris, he spent 8 years on leading teams for development of complex generics and biosimilars. Thereafter his focus shifted to auto-injectors and combination products.
Dirk is committed in helping drug and device developers to optimize time-to-market and smooth regulatory approval process in a global environment. The focus of his main enterprise anteris medical GmbH is strategic positioning, development, and registration of combination products, such as prefilled syringes, inhalers, and autoinjectors, on behalf of pharmaceutical and biotech customers worldwide.
Combination products, as the term implies, draw from the pharmaceutical and the medical device industries, and force developers and regulators into a complex and challenging evaluation of opportunities and risks. From a commercial perspective, market players act to prolong the commercial life of a product, counter a competitor’s move, increase the products value by offering additional value to the patient, or simply bring a product up to the standard of care. Whatever the change to the product, a series of regulatory, commercial, or supply chain consequences have to be considered to make the effort successful. The presentation is intended to provide insights into the highly dynamic LCM strategie for biologics and biosimilars.View Details